HCA
AMRX icon

Harbor Capital Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Harbor Capital Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16K Sell
1,313
-347
-21% -$4.66K ﹤0.01% 874
2025
Q4 		$21K Sell
1,660
-28
-2% -$320 ﹤0.01% 813
2025
Q3 		$17K Buy
+1,688
New +$15.2K ﹤0.01% 831

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Harbor Capital Advisors's AMRX Position: Q1 2026 in Review

Harbor Capital Advisors reduced its Amneal Pharmaceuticals (AMRX) stake by 21% in Q1 2026, selling an estimated $4.66K and leaving 1,313 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #874.

Harbor Capital Advisors first reported a position in AMRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $21K in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Harbor Capital Advisors held 1,313 shares of Amneal Pharmaceuticals worth $16K as of Q1 2026.
  • Harbor Capital Advisors sold 347 Amneal Pharmaceuticals shares in Q1 2026, an estimated $4.66K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Harbor Capital Advisors's portfolio in Q1 2026, its #874 holding.
  • Harbor Capital Advisors first reported a position in Amneal Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Harbor Capital Advisors's Amneal Pharmaceuticals position peaked at $21K in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.